Novelix Pharmaceuticals Ltd: Strong Q1 FY27 Performance

Rs 36.91 crore Revenue | Rs 1.18 crore Profit After Tax

Reader Takeaway: Stellar YoY profit growth driven by increased revenue in the bulk drug segment.

What just happened

Novelix Pharmaceuticals Ltd, formerly Trimurti Limited, announced its unaudited standalone financial results for the first quarter of fiscal year 2027, ending June 30, 2026. The company reported a robust year-over-year performance, with revenue from operations climbing by 65.1% to Rs 36.91 crore. Profit After Tax (PAT) saw a dramatic surge of 971.8%, reaching Rs 1.18 crore compared to Rs 0.11 crore in the same quarter last year.

Why this matters

The significant jump in profitability and revenue indicates a strong operational performance for Novelix Pharmaceuticals. For shareholders, this suggests a potential turnaround and improved financial health of the company, primarily in its core business of manufacturing and trading active pharmaceutical ingredients (APIs) or bulk drugs.

The backstory

Novelix Pharmaceuticals operates in the critical 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs)' segment. The company recently underwent a name change from Trimurti Limited, reflecting a shift or focus in its business activities. As of June 30, 2026, the company confirmed it has no subsidiaries, associates, or joint venture companies.

What changes now

This financial performance could lead to renewed investor interest. The substantial growth in PAT and revenue, along with a basic Earnings Per Share (EPS) of Rs 0.49, suggests the company is effectively capitalizing on its market position within the bulk drug sector. Management highlighted that due to the single business activity, segmental reporting is not separately presented.

Risks to watch

Operating in a single business segment, 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs)', presents a concentration risk. The company's performance is highly dependent on the dynamics of this specific market. Sustaining this level of growth against market volatility and competition will be key.

Peer comparison

[Grounded search unavailable for specific peer comparison in the bulk drug manufacturing segment for Novelix Pharmaceuticals Ltd. Information on direct competitors' recent performance is not readily available.]

Context metrics (time-bound)

Revenue from operations grew 65.1% year-over-year to Rs 36.91 crore for Q1 FY27.
Profit After Tax (PAT) increased by 971.8% year-over-year to Rs 1.18 crore for Q1 FY27.
Basic Earnings Per Share (EPS) was Rs 0.49 for Q1 FY27, up from Rs 0.09 in Q1 FY26.

What to track next

Investors will be watching for continued revenue growth and sustained profitability in upcoming quarters. Monitoring the company's expansion plans or diversification strategies within the pharmaceutical API space will also be crucial.